INDIVIDUAL TEST 517
Beta-2-Glycoprotein 1 Antibodies (IgG, IgM)
Indication
Suspicion of primary antiphospholipid syndrome (APS) and systemic lupus erythematous with secondary antiphospholipid syndrome (APS)
Sample material
Serum
- Minim. volume: 0,5 mL
Transport
- Within Sweden: room temperature
- International: cold
Method
ELISA
Reference interval
< 20 U/mL negative
Result
Results are reported as negative or positive with a concentration (U/mL).
Interpretation
Elevated levels of IgM and IgG antibodies against Beta-2-Glycoprotein-1 are included in the laboratory criteria for the antiphospholipid syndrome (APS), characterized by thrombotic tendency (arterial and/or venous), and/or pregnancy morbidity (miscarriage/preeclampsia/placental insufficiency).
The syndrome can be associated with SLE (secondary APS) but also occurs without signs of inflammatory systemic disease (primary APS). The highest risk for APS is triple positivity, i.e., the presence of antibodies against Beta-2-Glycoprotein-1 in combination with lupus anticoagulant and antibodies against Cardiolipin.
References
- Barbhaiya M et al. Ann Rheum Dis. 2023. 2023 ACR/EULAR antiphospholipid syndrome classification criteria. PMID: 37640450
- Cabrera-Marante O et al. Front Immunol. 2025. Criteria and non-criteria anti-phospholipid antibodies in the different clinical forms of antiphospholipid syndrome. PMID: 40821829
- Van Hoovels L et al. J Thromb Haemost. 2025. Multicenter study to improve clinical interpretation of anticardiolipin and anti-β2-glycoprotein I antibody test results for diagnosis of antiphospholipid syndrome. PMID: 40383153
Last updated: 2025-12-01
Can't find what you're looking for? We are here to help
ENSKILD ANALYS 517
Beta-2-Glykoprotein 1-antikroppar (IgG, IgM)
Indikation
Misstanke om primärt antifosfolipidsyndrom (APS) och systemisk lupus erytematosus.
Provmaterial
Serum
- Minim. volym: 0,5 mL
Transport
- Inom Sverige: rumstemperatur
- Internationellt: kylt
Metod
ELISA
Referensintervall
< 20 U/mL negativt
Resultat
Resultatet anges som negativt eller positivt med koncentration (U/mL).
Tolkning
Förhöjda nivåer av IgG- och IgM-antikroppar mot beta-2-glykoprotein-1 ingår i laboratoriekriterierna för antifosfolipidsyndrom (APS) som karakteriseras av trombosbenägenhet (arteriell och/eller venös) och/eller graviditetsmorbiditet (missfall/preeklampsi/placentainsufficiens).
Syndromet kan vara associerat med SLE (sekundärt APS), men förekommer även utan tecken på inflammatorisk systemsjukdom (primärt APS). Högst risk för APS utgör trippelpositivitet dvs förekomst av antikroppar mot beta-2-glykoprotein-1 i kombination med lupus antikoagulans och antikroppar mot kardiolipin.
Referenser
- Barbhaiya M et al. Ann Rheum Dis. 2023. 2023 ACR/EULAR antiphospholipid syndrome classification criteria. PMID: 37640450
- Cabrera-Marante O et al. Front Immunol. 2025. Criteria and non-criteria anti-phospholipid antibodies in the different clinical forms of antiphospholipid syndrome. PMID: 40821829
- Van Hoovels L et al. J Thromb Haemost. 2025. Multicenter study to improve clinical interpretation of anticardiolipin and anti-β2-glycoprotein I antibody test results for diagnosis of antiphospholipid syndrome. PMID: 40383153
Senast uppdaterat: 2025-12-01